Brentuximab

Brentuximab C화학적 특성, 용도, 생산

개요

Brentuximab verdotin was approved by the U.S. FDA in August 2011 for treatment of Hodgkin’s lymphoma (HL) in patients who have failed autologous stem cell transplant (ASCT) or ASCT ineligible patients who have failed at least two prior chemotherapy regimens, and for second line treatment of systemic anaplastic large cell leukemia (ALCL). Brentuximab verdotin is a chimeric (mouse V region/human C region) CD30 binding monoclonal antibody (cAC10) that is conjugated via cysteine residues to a small molecule comprising a cysteine reactive dipeptide linker moiety and the microtubule polymerization inhibitor monomethyl auristatin E(MMAE). The antibody component of the drug binds to CD30 expressing tumor cells, and the active cytotoxic component, MMAE, is released by proteolytic cleavage of the dipeptide linker moiety.

Clinical Use

Brentuximab vedotin is an antibody drug conjugate that is comprised of an anti-CD30 antibody and the potent tubulin based inhibitor monomethyl auristatin E (MMAE). These two entities are connected together via a linker consisting of a maleimide conjugation handle that includes an enzyme-cleavable valine-citrulline- para-aminobenzylcarbamate group. This conjugation handle releases MMAE after internalization of the conjugate by the cancer cell that recognizes the antibody. Brentuximab vedotin was discovered by Seattle Genetics who co-developed the conjugate with Millenium Pharmaceuticals. Brentuximab vendotin has been approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) and relapsed or refractory Hodgkin’s lymphoma. Brentuximab vedotin is also undergoing clinical trials for the treatment of CD30-expressing cutaneous T-cell lymphoma and CD30-positive hematologic malignancies. Although brentuximab vedotin is classified as a biologic, an exception has been made to include it in this year’s review because the small molecule portion of the conjugate was prepared by total synthesis.

Brentuximab 준비 용품 및 원자재

원자재

준비 용품

Brentuximab 공급 업체

공급자	전화	이메일	국가	제품 수	이점
Shanghai EFE Biological Technology Co., Ltd.	021-65675885 18964387627	info@efebio.com	China	9707	58
ShangHai Biochempartner Co.,Ltd	17754423994 17754423994	2853530910@QQ.com	China	8011	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1565	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10022	58
AntibodySystem	17762345272 18162686757	biolab-reagents@atagenix.com	China	9818	58
Hubei Qingbei Yunyan Pharmaceutical Technology Co., Ltd	18162595016; 18162595016	3287908757@qq.com	China	9102	58
Shanghai jerryxing Biomedical Technology Co., Ltd	17721492509	643638326@qq.com	China	5347	58
bioleaper	18601717983	guojing@bioleaper.com	China	5616	58
TargetMol Chemicals Inc.	15002134094	marketing@targetmol.cn	China	28091	58

Brentuximab 관련 검색: